{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aluminum+hydroxide&page=2",
    "query": {
      "intervention": "Aluminum hydroxide",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aluminum+hydroxide&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-26T16:05:08.036Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00001031",
      "title": "A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "rgp120/HIV-1MN",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rgp120/HIV-1 SF-2",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "16 Years to 60 Years"
      },
      "enrollment_count": 296,
      "start_date": null,
      "completion_date": "1997-12",
      "has_results": false,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-09-26T16:05:08.036Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • St Louis, Missouri • Rochester, New York + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001031"
    },
    {
      "nct_id": "NCT01250795",
      "title": "Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "HAI-05 Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Fraunhofer, Center for Molecular Biotechnology",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 100,
      "start_date": "2010-11",
      "completion_date": "2011-07",
      "has_results": false,
      "last_update_posted_date": "2016-05-12",
      "last_synced_at": "2026-09-26T16:05:08.036Z",
      "location_count": 2,
      "location_summary": "Wichita, Kansas • Kansas City, Missouri",
      "locations": [
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01250795"
    },
    {
      "nct_id": "NCT01701999",
      "title": "Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Botulism"
      ],
      "interventions": [
        {
          "name": "rBV A/B",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "California Department of Public Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "18 Years to 69 Years"
      },
      "enrollment_count": 45,
      "start_date": "2013-02",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2017-05-16",
      "last_synced_at": "2026-09-26T16:05:08.036Z",
      "location_count": 2,
      "location_summary": "Richmond, California • West Jefferson, Ohio",
      "locations": [
        {
          "city": "Richmond",
          "state": "California"
        },
        {
          "city": "West Jefferson",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01701999"
    },
    {
      "nct_id": "NCT00936429",
      "title": "Study of HBV-001 D1 in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dengue Fever"
      ],
      "interventions": [
        {
          "name": "DEN1-80E (HBV-001 D1 + 3.5 mg Alhydrogel)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for DEN1-80E",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Hawaii Biotech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 16,
      "start_date": "2009-07",
      "completion_date": "2011-01",
      "has_results": false,
      "last_update_posted_date": "2011-02-07",
      "last_synced_at": "2026-09-26T16:05:08.036Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00936429"
    },
    {
      "nct_id": "NCT06796686",
      "title": "Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "426c.Mod.Core-C4b",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HxB2.WT.Core-C4b",
          "type": "BIOLOGICAL"
        },
        {
          "name": "3M-052-AF adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aluminum hydroxide suspension (Alum) adjuvant",
          "type": "OTHER"
        },
        {
          "name": "Diluent",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 42,
      "start_date": "2025-03-17",
      "completion_date": "2027-01-15",
      "has_results": false,
      "last_update_posted_date": "2025-09-25",
      "last_synced_at": "2026-09-26T16:05:08.036Z",
      "location_count": 6,
      "location_summary": "San Francisco, California • Atlanta, Georgia • Decatur, Georgia + 2 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06796686"
    },
    {
      "nct_id": "NCT03783130",
      "title": "Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Human Immunodeficiency Virus Prevention",
        "Human Immunodeficiency Virus (HIV)"
      ],
      "interventions": [
        {
          "name": "VRC-HIVRGP096-00-VP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Alum Adjuvant",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 16,
      "start_date": "2019-03-07",
      "completion_date": "2020-06-24",
      "has_results": true,
      "last_update_posted_date": "2021-08-12",
      "last_synced_at": "2026-09-26T16:05:08.036Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03783130"
    },
    {
      "nct_id": "NCT00001052",
      "title": "A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Aluminum hydroxide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "QS-21",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rgp120/HIV-1MN",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 110,
      "start_date": null,
      "completion_date": "1997-09",
      "has_results": false,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-09-26T16:05:08.036Z",
      "location_count": 5,
      "location_summary": "St Louis, Missouri • Rochester, New York • Pittsburgh, Pennsylvania + 2 more",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001052"
    },
    {
      "nct_id": "NCT00057525",
      "title": "A New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anthrax"
      ],
      "interventions": [
        {
          "name": "Anthrax",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Alhdryogel or PBS",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "DynPort Vaccine Company LLC, A GDIT Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 70,
      "start_date": "2003-04",
      "completion_date": "2004-08",
      "has_results": false,
      "last_update_posted_date": "2011-06-30",
      "last_synced_at": "2026-09-26T16:05:08.036Z",
      "location_count": 1,
      "location_summary": "Rockville, Maryland",
      "locations": [
        {
          "city": "Rockville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00057525"
    },
    {
      "nct_id": "NCT05349617",
      "title": "Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chikungunya Virus"
      ],
      "interventions": [
        {
          "name": "CHIKV VLP/adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bavarian Nordic",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 413,
      "start_date": "2022-05-12",
      "completion_date": "2023-08-08",
      "has_results": true,
      "last_update_posted_date": "2024-12-13",
      "last_synced_at": "2026-09-26T16:05:08.036Z",
      "location_count": 10,
      "location_summary": "Miami, Florida • Miami Lakes, Florida • St. Petersburg, Florida + 7 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05349617"
    },
    {
      "nct_id": "NCT00705835",
      "title": "Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) Plus the Immunological Adjuvant Alhydrogel",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "rsPSMA protein plus Alhydrogel® vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 14,
      "start_date": "2003-01",
      "completion_date": "2008-01",
      "has_results": false,
      "last_update_posted_date": "2012-01-09",
      "last_synced_at": "2026-09-26T16:05:08.036Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00705835"
    }
  ]
}